SELLAS Life Sciences ($SLS): The “Doctor,” the Death Clock, and the $3 Billion Delusion – BMF Reports

SELLAS says its 80-death Phase 3 trial has at least 90% power to detect a hazard ratio of 0.636.

Run the same assumptions through a standard survival-analysis model, and the power comes out closer to 51%, with roughly 205 deaths needed to actually reach 90%. The report widens from there: a nearly $3 billion valuation resting on a small, non-randomized historical dataset, a blinded interim result that only cleared futility (not efficacy), and a share count that has more than doubled in 17 months. BMF Reports / BMF Capital, which discloses a short position in SLS, argues the stock does not need fraud to collapse. It only needs REGAL to be less miraculous than the price already assumes.

Ticker: SLS (SELLAS Life Sciences)
Research Firm: BMF Reports / BMF Capital
Report URL: https://bmfreports.com/articles/sls?ref=shortreport.fyi
Position Disclosure: "BMF Reports / BMF Capital Is Short NASDAQ: $SLS."

Thesis

BMF Reports argues that SELLAS's roughly $2.93 billion valuation depends on investors reading efficacy into a trial design and prior evidence base that, examined closely, does not support it.

• Power Math Mismatch: REGAL's published design claims at least 90% power at a hazard ratio of 0.636 with 80 final deaths. The author's Lan-DeMets/O'Brien-Fleming reconstruction puts actual power at that hazard ratio near 51%, and calculates that roughly 205 deaths, not 80, would conventionally be required to reach 90% power.
• Significance Threshold Reframed: SELLAS's 2022 disclosures described a hazard ratio of 0.636 (12.6 months GPS versus 8 months for best available treatment) as the threshold for statistical significance, not as a 90%-powered treatment-effect assumption the way it is now framed.
• Ten-Patient Foundation: GPS advanced into Phase 3 on a filing-level comparison of 10 vaccine-treated AML patients against 15 non-randomized historical controls, drawn from work peer-reviewed literature describes as a 16-patient pilot study. Disease-free survival in that dataset missed significance (319 versus 131 days, p=0.19) even as overall survival cleared it (495 versus 165 days, p=0.0175).
• Non-Efficacy Interim: REGAL's interim analysis at 60 deaths did not stop for efficacy. The independent monitoring committee only found that the trial exceeded futility criteria; the author estimates a hazard ratio near 0.56 or better would have been needed to stop early on efficacy grounds.
• Undisclosed Interim Detail: SELLAS has not disclosed the futility boundary, observed hazard ratio, conditional power, treatment-arm event split, or confidence interval from that interim analysis. Investors know only that the trial continued.
• Equity Dilution Machine: Basic shares outstanding rose approximately 122%, from 90.8 million in March 2025 to 201.9 million in August 2026. A further 35.3 million shares (about 17.5% of the basic count) sit reserved for warrants, options, RSUs and equity plans, and a $150 million ATM with TD Cowen, entered March 2026, remained fully unused through June 30.
• Failed China Catalyst: SELLAS's 2022 guidance pointed to roughly 20 Chinese REGAL patients and low-teen-millions of dollars of partner cash in the first half of 2023. No Chinese patients had enrolled by the end of 2025, and in July 2026 an arbitrator dismissed SELLAS's $13 million milestone claim against partner 3D Medicines, allocating roughly $1 million of the partner's legal costs back to SELLAS.
• Credential Wording: CEO Angelos Stergiou is identified in SEC filings as "M.D., Sc.D. h.c." The Sc.D. is honorary, and the World Directory of Medical Schools identifies his M.D.-granting "U.S. American Institute of Medicine" as the University of Seychelles American Institute of Medicine, a school that closed in 2013. The author states it found no evidence the degree was fabricated.

Catalysts

• REGAL's final overall-survival analysis at the 80th death (no date disclosed): the actual hazard ratio and significance outcome will either validate or undercut the market's current read of the trial.
• Any disclosure of the interim futility boundary, observed hazard ratio, or conditional power from the 60-death analysis: would let investors judge how close REGAL actually came to failing.
• Drawdown of the $150 million TD Cowen ATM facility, unused through June 30: any usage signals further share issuance.
• Exercise of the 35.3 million shares reserved for warrants, options, RSUs and equity plans as of June 30: would add roughly 17.5% to the current basic share count.
• Progress or results from the ongoing randomized first-line Phase 2 trial of SLS009: could establish value independent of the GPS/REGAL outcome.
• GPS patent expirations beginning in 2026: narrows the intellectual-property runway on the actual product in REGAL, distinct from the 2040 GPS+ patent life often cited.

Company Response

The source report does not describe any request for comment sent to SELLAS, and no response from SELLAS, 3D Medicines, Angelos Stergiou, or John Burns is reported.

Notable Details

• At roughly a $2.93 billion equity value, SELLAS operates with only 13 full-time employees and $138.3 million in cash, a gap the report frames as almost entirely a bet on a single blinded trial outcome.
• The company's frequently cited 2040 patent protection applies to GPS+, a seven-peptide product family; the four-peptide GPS product actually being tested in REGAL has patent expirations beginning in 2026.
• CEO compensation reached approximately $1.88 million in 2025 at a still pre-revenue company, alongside a board-approved 20 million-share expansion of the equity incentive plan; directors and executive officers collectively held about 1.3% of the company as of April 2026, most of the CEO's stake made up of exercisable options rather than owned shares.
• SELLAS has repeatedly used financing agents Maxim and A.G.P., both of which settled prior SEC and, in Maxim's case, FINRA matters; the report explicitly states this history does not establish that any SELLAS offering was improper.

"SELLAS does not need to be fraudulent for SLS to collapse. REGAL only needs to be less miraculous than the valuation already assumes."

This appears in the report's summary of the short thesis, distilling the argument that SELLAS's valuation already assumes an unusually successful Phase 3 outcome.

FAQs

What is SLS stock and why is a short seller targeting it?

SLS is the Nasdaq ticker for SELLAS Life Sciences, a clinical-stage oncology company whose lead program, GPS, is being tested in the Phase 3 REGAL trial. BMF Reports, which holds a short position in SLS, argues the stock's roughly $2.93 billion valuation assumes a level of REGAL efficacy that the trial's own design and prior clinical evidence do not support.

What does SELLAS Life Sciences do, and what is GPS?

SELLAS Life Sciences is developing galinpepimut-S (GPS), a four-peptide immunotherapy intended to trigger T-cell responses against WT1, a protein overexpressed in acute myeloid leukemia and other cancers. GPS is being tested as a maintenance treatment in the REGAL Phase 3 trial against investigator-selected best available treatment, with overall survival as the primary endpoint.

Who is BMF Reports / BMF Capital, and what do they allege about SELLAS?

BMF Reports / BMF Capital is the author and publisher of the short report on SELLAS and discloses that it is short NASDAQ: SLS. The firm alleges that REGAL's stated statistical power does not reconcile with standard survival-analysis math, that the underlying GPS efficacy case rests on a small historical-control dataset, and that a merely non-extraordinary REGAL result could sharply reprice the stock given SELLAS's dilution and cash position.

What is REGAL, and when will investors get a final answer?

REGAL is SELLAS's pivotal Phase 3 trial, enrolling roughly 126 adult AML patients in second complete remission after salvage therapy, randomized 1:1 to GPS or best available treatment. The trial is designed for an interim analysis at 60 deaths and a final analysis at 80 deaths; as of the report date, the interim analysis had passed without stopping for efficacy, and the final read had not yet occurred.

Why does the report question SELLAS's "90% power" claim?

The published REGAL design states at least 90% power to detect a hazard ratio of 0.636 with 80 deaths, but the report's Lan-DeMets/O'Brien-Fleming reconstruction calculates only about 51% power under those same assumptions. It estimates a hazard ratio near 0.48, not 0.636, would be needed to actually reach 90% power with 80 deaths, or alternatively that roughly 205 deaths would be needed to hit 90% power at HR 0.636.

What is the issue with SELLAS CEO Angelos Stergiou's medical degree?

SELLAS's SEC filings describe Stergiou's M.D. as coming from the "U.S. American Institute of Medicine" and list a "Sc.D. h.c." credential. The World Directory of Medical Schools identifies the M.D.-granting institution as the University of Seychelles American Institute of Medicine, located in Seychelles, which closed in 2013; the Sc.D. is honorary. The report states it found no evidence the degree itself was fabricated, but says the wording creates a misleading impression.

How much has SELLAS diluted shareholders, and is more dilution coming?

Basic shares outstanding rose from about 90.8 million in March 2025 to 201.9 million in August 2026, an increase of roughly 122% in 17 months. As of June 30, an additional 35.3 million shares were reserved for warrants, options, RSUs and equity plans, and a $150 million ATM facility with TD Cowen, entered in March 2026, had not been used at all.

What is the report's downside case if REGAL disappoints?

The report estimates a clean-failure equity value of approximately $3.50 per share, built from cash, the SLS009 program, and remaining platform value after cash burn. Against the report date price of $14.50 per share, that estimate implies roughly 76% downside if REGAL's outcome falls short of what the current valuation assumes.

Disclaimer: This summary is not primary research and does not constitute investment advice. It is a brief overview of a detailed equity research report authored by the firm, organization, or source referenced in this article or at https://bmfreports.com/articles/sls, which contains extensive evidence, regulatory filings, and analysis; readers are encouraged to review the full report there for a comprehensive understanding. The content provided in this publication is not authored or originated by us — we act solely as a distributor and do not endorse, verify, or take responsibility for the accuracy, completeness, or reliability of the information presented. This publication is for informational purposes only and should not be construed as legal, business, investment, or tax advice. Always conduct independent due diligence and consult qualified professionals before making any decisions based on the information contained herein. We disclaim all liability for any loss or damage arising from reliance on third-party content, and the views expressed are solely those of the respective source and do not necessarily reflect our own.